255 results about "Exacerbation" patented technology

A system and related method for identifying a trigger event to a patient health-related exacerbation. The system includes at least one sensor configured to collect data related to the patient health-related exacerbation, an analyzer configured to validate the collected data, a patient interface device configured to receive patient inputs to at least one question, and an identifier device configured to receive the patient inputs and collected data and identify the trigger event. The system may also include an expert system configured to receive the patient inputs and the validated collected data and identify a primary patient disease, and a reporting device configured to generate reports related to the identified primary patient disease, patient inputs, and sensed patient conditions.

A method for monitoring the progression of the hemodynamic status of a patient by tracking autonomic tone. For example, the method may be applied to patients suffering from heart failure, diabetic neuropathy, cardiac ischemia, sleep apnea and hypertension. An implantable or other ambulatory monitor senses a pulse amplitude signal such as a vascular plethysmography signal. Variations of the signal amplitude on a scale greater than the heartbeat to heartbeat scale are indicative of variations in autonomic tone. A significant reduction in pulse amplitude and pulse amplitude variability are indicative of a heart failure exacerbation or other disease state change. This information may be used to warn the patient or healthcare providers of changes in the patient's condition warranting attention.

A computer-implemented method and system are provided for assisting a plurality of patients manage chronic health conditions. The method, for each patient, comprises: (a) receiving information from the patient or a member of a patient care network on an expected patient activity at a given future time period; (b) determining expected transient local ambient conditions in the patient's surroundings during the expected patient activity at the given future time period; (c) predicting health exacerbations for the patient using a stored computer model of the patient based on a desired patient control set-point range, the expected patient activity, and the expected transient local ambient conditions; and (d) proactively sending a message to the patient or a member of the patient care network before the given future time period, the message alerting the patient or a member of the patient care network of the predicted health exacerbations for the patient and identifying one or more corrective actions for the patient to avoid or mitigate the predicted health exacerbations.

An occluding hearing aid having anti-occlusion effect techniques combined with at least one improvement which, in the preferred embodiment, includes enhancement of acoustic output in the lower-midrange and bass frequency regions, typically between substantially 40 and 500 Hz, which regions are crucial for natural reproduction of multimedia sound and music but are not optimally processed, and generally not provided at all, in prior art hearing aids in order to avoid exacerbation of the occlusion effect. In specific embodiments, the hearing aid of the present invention includes primary or first microphone exposed to external sound plus a secondary or second microphone exposed to sound within an ear canal, in which a signal produced by the secondary microphone is applied as negative feedback to an input of a non-gain controlling signal process and amplifier driving a hearing aid receiver (transducer), whereby, it has been determined by the present inventor, the occlusion effect may be substantially canceled. The hearing aid further comprises at least one of ten combinational improvements each providing substantial performance benefits over known techniques and devices.

An exemplary method includes delivering a cardiac resynchronization therapy using an atrio-ventricular delay parameter and an interventricular delay parameter, measuring an atrio-ventricular conduction delay, measuring an interventricular conduction delay, assessing heart failure and/or cardiac resynchronization therapy performance based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay and determining at least one of an atrio-ventricular delay parameter value and an interventricular delay parameter value based at least in part on the measured atrio-ventricular conduction delay and the measured interventricular conduction delay. Other exemplary technologies are also disclosed.

The system described herein collects patient data passively and non-passively via onboard and external sensors, and combines the data with past clinical history to generate digital biomarkers. The collected data can also be further combined with other data generating systems to more accurately predict disease exacerbations. The system monitors the digital biomarkers in real-time, and can detect a change in the disease state prior to clinical decompensation and suggest pre-emptive intervention. The system enables a patient to be treated early in the clinical timeline when the disease exacerbation is at the subclinical level rather than waiting until the disease exacerbation reaches the clinical level. Acting when the exacerbation is at the subclinical level enables preemptive treatment rather than reactive treatment, which is often more cost effective while improving clinical outcomes. The system is able to make the predictions by detecting subclinical changes in digital biomarkers that are generated from respiratory, cardiac, patient reported symptoms, user behaviors, and environmental triggers.

A system and method for providing chronic obstructive pulmonary disease (COPD) exacerbation risk notifications in real time or near-real time is described. Rescue and controller medication events are detected by sensors associated with the patient's medicament device/s, and provide a basis to determine to rescue and controller medication use trends for the patient. This data is analyzed to determine the patient's risk for COPD exacerbation after each event, and is used to send notifications to one or both of the patient and their health care provider.

The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing/remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing/remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing/remitting disease as seen with multiple sclerosis.

The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made.

Systems and methods assist with managing a chronic disease of a user such as a chronic respiratory or cardiac disease. The system may include a physiological monitor adapted to be carried by the user and operative to sense a physiological parameter of the user. The system may include a management device operatively coupled with the physiological monitor to receive the sensed physiological parameter of the user. The management device, such as with an included processor, may be configured to analyze the physiological and/or environmental parameters to detect a trigger pattern of the parameters, the trigger pattern indicative of a probable event of exacerbation of the chronic respiratory and/or cardiac condition. The management device may then generate automated responses based on the trigger pattern such as by providing instructions for activities and/or treatment for the chronic condition.

The invention discloses apparatus, systems and methods for detecting a severity change in respiratory insufficiency or chronic obstructive pulmonary disease. The supplied pressure may optionally be determined during pressure treatment that satisfies a target ventilation. The supplied pressure or representative data may be compared to one or more thresholds that are selected to represent a change in the condition of the RI or COPD patient such as an exacerbation of a prior condition. Results of the comparisons may trigger one or more warnings or messages to notify a patient or physician of a pending change to the patient's RI or COPD condition so that the patient may more immediately seek medical attention to treat the condition.

The present invention provides methods of treating and preventing mortality associated with heart failure and renal insufficiency in a Stage B, C, or D heart failure patient, and for improving quality of life by providing improved methods of administering a therapeutically effective amount CGRP. One method comprise administering between about 50 and about 500 ng/min of CGRP for a time between 30 minutes and 8 hours per day for as many days as needed to provide symptomatic relief, prevent exacerbation of symptoms, and/or prevent and/or delay progression of the disease state of heart failure in said patient. The therapies can be administered on an outpatient or inpatient basis.

The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca⁺² to Na⁺ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

The invention relates to a parenteral preparation containing active entecavir and a preparation method thereof. The invention is characterized in that the parenteral preparation comprises the active entecavir, xylitol, water-soluble filler, pH regulator, water for injection and osmo-regulator, wherein the active entecavir is 0.001 percent to 30 percent by weight, and the balance is pharmaceutic adjuvant or water. The parenteral preparation has the advantages of good stability and high bioavailability, thus solving the defects of the oral administration of entecavir in treating the acute exacerbation of viruses. The parenteral preparation is particularly suitable for treatment on the acute exacerbation of hepatitis of a diabetic.

The present invention relates to N-acetylcysteine compositions and methods for treating inflammation and redox imbalance in acute exacerbations of inflammatory lung disease.

Various antibodies with different binding characteristics for MBL A or MBL B bound to mannan or MBL A or MBL B bound to an antibody against MBL are provided. Also provided are methods for selecting antibodies against MBL with different binding characteristics and methods and kits for using these antibodies to measure MBL capable of binding to mannan or oligomerized MBL and abnormal, poorly oligomerized MBL in a sample. The methods and kits are useful in diagnosing increased susceptibility to and exacerbation of infections and autoimmune diseases.

An apparatus, such as a pressure support ventilator or respiratory monitor, provides operations for a patient, such a patient with heart failure, Chronic Obstructive Pulmonary Disease or other respiratory insufficiency. In some embodiments, the apparatus may detect a respiratory condition, such as a decompensation event and/or exacerbation event, from respiratory parameters. A clinical alert message may be transmitted or displayed for a physician based on the results of query presented to the patient in response to an analysis of the one or more respiratory parameters. In some embodiments, the apparatus generates a potential relapse indicator that may provide a prediction of a risk of an oncoming clinical event such as for evaluating whether to release the patient from a hospital.

The present invention relates to a method for detecting one or more indicator(s) of the probable onset of a chronic obstructive pulmonary disease (COPD) exacerbation; primers for use in the method; a computer model using detection of one or more indicator(s) to the probable onset of a COPD exacerbation for patient management and the prophylactic or curative treatment of COPD exacerbation and to a prognostic and/or diagnostic test for use in the detection of one or more indicator(s) to the probable onset of a COPD exacerbation.

The invention relates to a Chinese medicinal composition for treating cholecystitis diseases and a preparation method thereof. The invention discloses the novel Chinese medicinal composition for treating the cholecystitis diseases and the preparation method thereof. The Chinese medicinal composition is mainly prepared from the following raw material medicaments: tangerine peel, immature bitter orange, Chinese eaglewood, costustoot, nutgrass galingale rhizome, Szechuan lovage rhizome, rhizoma corydalis, turmericroot-tuber, turmeric, radix rehmanniae preparata, white paeony root, Chinese angelica, root of straight ladybell, dendrobium, Mongolian snakegourd root, gardenia, baical skullcap root, golden thread, amur corktree bark, Chinese gentian, ash bark, lightyellow sophora root, fresh rehmannia root, tree peony bark, red paeony root, buffalo horn, honeysuckle flower, dandelion, violet, chrysanthemum, natural indigo, common lophatherum herb, figwort root, glabrous greenbrier rhizome, Chinese lobelia herb, spreading hedyotis herb, cortex lycii radicis, peach seed, safflower, kudzu-vine rootand antelope horn. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms of cholecystitis diseases such as chest stuffiness, indigestion, nausea, inappetence and the like, severe colicky pain of stomach, paroxysmal exacerbation, and pain generally radiating to right shoulders or right backs, and also obviously improve symptoms such as nausea, emesis, sensation of chill, fever and the like during severe illness state. The Chinese medicinal composition has the advantages of low cost, basically no toxic or side effects and the like because of basically combing edible and pharmaceutical medicaments specified in national formulary.

The invention relates to a novel oral enteric preparation which is composed of 0.1-1000mg of Grel drugs, or medically acceptable salts, ester or derivatives, 37.5-325mg of aspirin and at least one medically acceptable load, wherein the Grel drugs, or medically acceptable salts, esters or derivatives are clopidogrel, prasugrel, brilinta, sarpogrelate, ozagrel, anagrelide, pamicogrel, or medically acceptable salts, ester or derivatives, preferably, clopidogrel sulfate. The oral enteric preparation is used for curing acute coronary syndrome (ACS), angor pectoris, stroke, myocardial infarction or cardia cerebrovascular diseases of patients. According to the oral enteric preparation, adverse reactions such as functional gastrointestinal disorders, nausea, vomit, gastritis, concealed hemorrhage, ulcer exacerbation and gastrointestinal bleeding caused by strong stimulus of aspirin to stomach can be avoided.